Idioma:

Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data

Elmunzer, B Joseph ; Higgins, Peter D R ; Saini, Sameer D ; Scheiman, James M ; Parker, Robert A ; Chak, Amitabh ; Romagnuolo, Joseph ; Mosler, Patrick ; Hayward, Rodney A ; Elta, Grace H ; Korsnes, Sheryl J ; Schmidt, Suzette E ; Sherman, Stuart ; Lehman, Glen A ; Fogel, Evan L

The American journal of gastroenterology, 2013-03, Vol.108 (3), p.410-415 [Periódico revisado por pares]

United States: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins

Sem texto completo

Citações Citado por

Enviar para

Título:
Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data
Autor: Elmunzer, B Joseph ; Higgins, Peter D R ; Saini, Sameer D ; Scheiman, James M ; Parker, Robert A ; Chak, Amitabh ; Romagnuolo, Joseph ; Mosler, Patrick ; Hayward, Rodney A ; Elta, Grace H ; Korsnes, Sheryl J ; Schmidt, Suzette E ; Sherman, Stuart ; Lehman, Glen A ; Fogel, Evan L
Assuntos: Administration, Rectal ; Adult ; Aged ; Cholangiopancreatography, Endoscopic Retrograde - adverse effects ; Cholangiopancreatography, Endoscopic Retrograde - economics ; Cost-Benefit Analysis ; Female ; Gastroenterology ; Humans ; Indomethacin - administration & dosage ; Indomethacin - economics ; Indomethacin - therapeutic use ; Male ; Middle Aged ; Pancreatitis - economics ; Pancreatitis - etiology ; Pancreatitis - prevention & control ; Prospective Studies ; Retrospective Studies ; Risk Factors ; Stents - economics ; Treatment Outcome
É parte de: The American journal of gastroenterology, 2013-03, Vol.108 (3), p.410-415
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: A recent large-scale randomized controlled trial (RCT) demonstrated that rectal indomethacin administration is effective in addition to pancreatic stent placement (PSP) for preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in high-risk cases. We performed a post hoc analysis of this RCT to explore whether rectal indomethacin can replace PSP in the prevention of PEP and to estimate the potential cost savings of such an approach. We retrospectively classified RCT subjects into four prevention groups: (1) no prophylaxis, (2) PSP alone, (3) rectal indomethacin alone, and (4) the combination of PSP and indomethacin. Multivariable logistic regression was used to adjust for imbalances in the prevalence of risk factors for PEP between the groups. Based on these adjusted PEP rates, we conducted an economic analysis comparing the costs associated with PEP prevention strategies employing rectal indomethacin alone, PSP alone, or the combination of both. After adjusting for risk using two different logistic regression models, rectal indomethacin alone appeared to be more effective for preventing PEP than no prophylaxis, PSP alone, and the combination of indomethacin and PSP. Economic analysis revealed that indomethacin alone was a cost-saving strategy in 96% of Monte Carlo trials. A prevention strategy employing rectal indomethacin alone could save approximately $150 million annually in the United States compared with a strategy of PSP alone, and $85 million compared with a strategy of indomethacin and PSP. This hypothesis-generating study suggests that prophylactic rectal indomethacin could replace PSP in patients undergoing high-risk ERCP, potentially improving clinical outcomes and reducing healthcare costs. A RCT comparing rectal indomethacin alone vs. indomethacin plus PSP is needed.
Editor: United States: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 8 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data

Elmunzer, B Joseph ; Higgins, Peter D R ; Saini, Sameer D ; Scheiman, James M ; Parker, Robert A ; Chak, Amitabh ; Romagnuolo, Joseph ; Mosler, Patrick ; Hayward, Rodney A ; Elta, Grace H ; Korsnes, Sheryl J ; Schmidt, Suzette E ; Sherman, Stuart ; Lehman, Glen A ; Fogel, Evan L

United States: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins

Buscando em bases de dados remotas. Favor aguardar.